欢迎来到天天文库
浏览记录
ID:48798263
大小:276.00 KB
页数:52页
时间:2020-01-25
《肺癌的生物靶向治疗进展.ppt》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、肺癌的生物靶向治疗进展上海市肺科医院肿瘤科CurrentAnti-CancerApproachesSurgeryChemo-therapyRadiationHormonaltherapyTargetedtherapyRemoveknowntumormassesKillrapidlydividingtumorcells,includingtumorcellsinadjacenttissuesKillrapidlydividingtumorcellsInhibitthegrowthandsurvivalofh
2、ormone-dependenttumorcellsSpecificallyinhibitprocessesrequiredfortumorcellgrowthWhydoweneednewanticanceragents?*1-yearsurvivalrateDatafromtheEUROCAREIIstudy80706050403020100Relative5-yearsurvivalrate(%)BreastColonKidneyLiverLung*OvaryPancreas1978–1980198
3、4–19861987–1989Whatmakesanidealtherapeutictarget?PresentinthemajorityofpatientswithspecifictumortypeCausativelinkwithtumourigenesisEssentialfunctionintumorcellsAssessingnoveltargetedagentsTypicalcytotoxicMTDOBDToxicityAntitumoureffectEffectTargetDoseOBD>MT
4、DAdaptedfromRowinsky2000TargetToxicityAntitumoureffectOBDMTDEffectOBD5、dwithinvasionmetastasislate-stagediseasechemotherapyresistancehormonaltherapyresistancepooroutcomeEGFRhighlyexpressedinNSCLCExtensiveclinicalexperiencewithgefitinibMonotherapyIDEAL1IDEAL25PhaseItrialsCombinationtherapyINTACT1INTACT2ExpandedAccessProgrammeP6、ost-marketinguseinJapanOthersalesOtherNSCLCstudiesTrialsinothertumourtypesn209216270720684~39,200~39,100~9100~6002600TOTAL~92,750Dataasof3Sept2003IDEAL,IRESSADoseEvaluationinAdvancedLungcancerINTACT,IRESSANSCLCTrialAssessingCombinationTreatmentRandomisatio7、nGefitinib250mgoncedailyGefitinib500mgoncedailyPatientsAdvancedNSCLChavingreceived1or2(IDEAL1)or>2(IDEAL2)previouschemotherapyregimensContinuegefitinibuntildiseaseprogressionorunacceptabletoxicityPrimaryendpointsResponserate(bothtrials)Safetyprofile(8、IDEAL1)Symptomrelief(IDEAL2)IDEAL1:platinum,1or2priorregimens(n=209)IDEAL2:platinumanddocetaxel,>2priorregimens(n=216)GefitinibPhaseIIstudies:IDEAL1&2Tumourresponse:IDEAL1&2(250mg/day)Objectiveresponserate=
5、dwithinvasionmetastasislate-stagediseasechemotherapyresistancehormonaltherapyresistancepooroutcomeEGFRhighlyexpressedinNSCLCExtensiveclinicalexperiencewithgefitinibMonotherapyIDEAL1IDEAL25PhaseItrialsCombinationtherapyINTACT1INTACT2ExpandedAccessProgrammeP
6、ost-marketinguseinJapanOthersalesOtherNSCLCstudiesTrialsinothertumourtypesn209216270720684~39,200~39,100~9100~6002600TOTAL~92,750Dataasof3Sept2003IDEAL,IRESSADoseEvaluationinAdvancedLungcancerINTACT,IRESSANSCLCTrialAssessingCombinationTreatmentRandomisatio
7、nGefitinib250mgoncedailyGefitinib500mgoncedailyPatientsAdvancedNSCLChavingreceived1or2(IDEAL1)or>2(IDEAL2)previouschemotherapyregimensContinuegefitinibuntildiseaseprogressionorunacceptabletoxicityPrimaryendpointsResponserate(bothtrials)Safetyprofile(
8、IDEAL1)Symptomrelief(IDEAL2)IDEAL1:platinum,1or2priorregimens(n=209)IDEAL2:platinumanddocetaxel,>2priorregimens(n=216)GefitinibPhaseIIstudies:IDEAL1&2Tumourresponse:IDEAL1&2(250mg/day)Objectiveresponserate=
此文档下载收益归作者所有